SLS - Sellas Life Sciences Group Inc logo

Sellas Life Sciences Group Inc

SLS

SELLAS Life Sciences Group develops novel cancer therapeutics, focusing on peptide immunotherapy galinpepimut-S and CDK9 inhibitor SLS009. The company partners with Merck & Co. and others to advance treatment options for various cancer types.

โš•๏ธ Healthcare NASDAQ Listed 2017 $ USD
$1,000 invested 10 years ago โ†’$1today

Score Overview

1 Year
Scoreโ€”
Net Growth-20.84%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score3.2
Net Growth-56.82%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth-100.00%
Rev TrendNever
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-36.65%
Net Trend56%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Sellas Life Sciences Group Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. SLS does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 11.54โ€”
1 Year2025-10-23
$ 1.916x
5 Years2021-10-22
$ 8.7232.34%
10 Years2016-10-21
$ 8.49K-99.86%
All Time2017-12-29
$ 393.00-97.06%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 32M$ 138M
2025$ 0.00-$ 26M$ 71M
2024$ 0.00-$ 30M$ 13M
2023$ 0.00-$ 37M$ 2M
2022$ 1M-$ 41M$ 17M
2021$ 7M-$ 20M$ 21M
2020-$ 16M$ 35M
2019$ 0.00-$ 19M$ 7M
2018$ 0.00-$ 27M$ 5M
IPO2017$ 0.00-$ 23M$ 2M
SLS - Sellas Life Sciences Group Inc logo

Sellas Life Sciences Group Inc fundamental performance

Between 2020 and 2025, net income went from -$ 16M to -$ 26M. Revenue increased in 0 of those 5 years; net income in 3.

Sellas Life Sciences Group Inc currently holds a 5-year HDB Score of 3.2 out of 10. How the HDB Score is calculated.

Membership

Explore SLS with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies